Gary Kaufman, MD
Internal Medicine · Chicago, ILNPI 1447252457
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,000 of the $4,389 with a category attached, or 91.1%. Gilead accounts for 91.1% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2024 at $4,135 and has fallen 97.9% since, to $85 in 2025. Among internal medicine clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 20 payments — averaging $219.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$4K
- GSK$129
- Cranial Technologies, Inc$73
- Exact Sciences$69
- Lilly USA, LLC$28
- Seqirus USA Inc$26
- plus $64 from 3 others
What the payments were for
- Consulting fees$4,00091%
- Food & beverage$3899%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 1 | $4,000 |
| GSK | 6 | $129 |
| Cranial Technologies, Inc | 5 | $73 |
| Exact Sciences | 3 | $69 |
| Lilly USA, LLC | 1 | $28 |
| Seqirus USA Inc | 1 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| AstraZeneca | 1 | $23 |
| Redhill Biopharma Inc. | 1 | $16 |
How this compares
$4,389 in reported general payments places this provider in the 90th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 68 | $74,410 |
| TradjentaLinagliptin | 19 | $13,866 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 18 | $10,610 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $7,732 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 19 | $5,006 |
| VascepaIcosapent Ethyl | 12 | $4,991 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 64 | $2,547 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $1,767 |
| Wixela InhubFluticasone Propion/Salmeterol | 12 | $1,633 |
| Rosuvastatin Calcium | 90 | $1,500 |
| Ultra-Fine Short Pen NeedlePen Needle, Diabetic | 16 | $1,043 |
| Pro Comfort Alcohol PadsAlcohol Antiseptic Pads | 19 | $1,000 |
| Atorvastatin Calcium | 145 | $840 |
| Nifedipine ErNifedipine | 40 | $761 |
| Tamsulosin Hcl | 41 | $759 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $129 | $7,73213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Chicago
- Merle DiamondChicago$1.1M
- Robert KushnerChicago$516K
- Romeo UrsuaChicago$420K
- Peter O DonnellChicago$318K
- George UrbanChicago$258K
- Kristen PallokChicago$256K
- George NissanChicago$252K
- Luke LaffinChicago$162K
- Daniel CatenacciChicago$161K
- Hiren ShahChicago$144K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.